Chemotherapy-refractory large B-cell lymphomas reprogrammed to respond to Azacitidine
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.